Protalix BioTherapeutics, Inc. (PLX) Capital expenditures 2016–2025
Protalix BioTherapeutics, Inc. (PLX) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$1.6MFY2025 · since FY2016: $849,000 → $1.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.6M | +27.8% |
| FY2024 | $1.3M | +11.6% |
| FY2023 | $1.1M | +83.0% |
| FY2022 | $628,000 | -57.0% |
| FY2021 | $1.5M | +122.7% |
| FY2020 | $655,000 | +4.5% |
| FY2019 | $627,000 | -8.6% |
| FY2018 | $686,000 | -29.4% |
| FY2017 | $971,000 | +14.4% |
| FY2016 | $849,000 | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice